Neutrophil–Lymphocyte Ratio as a Prognostic Marker in Adrenocortical Carcinoma

2021 ◽  
pp. 1-6
Author(s):  
Mirsala Solak ◽  
Ivana Kraljević ◽  
Karin Zibar Tomšić ◽  
Marko Kaštelan ◽  
Luka Kakarigi ◽  
...  
Keyword(s):  
Prognostic Marker ◽  
Adrenocortical Carcinoma ◽  
Neutrophil Lymphocyte Ratio ◽  
Lymphocyte Ratio

Capecitabine monotherapy and the clinical significance of neutrophil-lymphocyte ratio versus platelet-lymphocyte ratio in patients with metastatic colorectal cancer.

2012 ◽  
Vol 30 (4_suppl) ◽  
pp. 660-660 ◽  
Author(s):  
Suee Lee ◽  
Hyuk-Chan Kwon ◽  
Sung-Hyun Kim ◽  
Sung Yong Oh ◽  
Ji Hyun Lee ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Disease Control ◽  
Metastatic Colorectal Cancer ◽  
Prognostic Marker ◽  
Univariate Analysis ◽  
Hazard Ratio ◽  
Neutrophil Lymphocyte Ratio ◽  
Lymphocyte Ratio ◽  
Platelet Lymphocyte Ratio ◽  
Third Line

660 Background: Oxaliplatin- and irinotecan-based combination chemotherapy with infusional 5-FU and leucovorin are currently the standard therapies for metastatic colorectal cancer. The objectives of this study were to evaluate the efficacy of capecitabine monotherapy as third line therapy for metastatic colorectal cancer after failure of chemotherapy containing oxaliplatin and irinotecan, and to determine whether the neutrophil-lymphocyte ratio (NLR), or the platelet-lymphocyte ratio (PLR) are significant prognostic marker in metastatic colorectal cancer. Methods: We analyzed 60 patients with metastatic colorectal cancer who received capecitabine monotherapy after the failure of FOLFOX and FOLFIRI. Capecitabine was administered at 1250mg/m2 twice daily for 2 weeks, every 3 weeks. The NLR and PLR were calculated from complete blood counts in baseline laboratory test before the first cycle chemotherapy. Results: The overall response rate was 6.7% and stable disease was 41.7%. The disease control rate was 48.3%. The median progression-free survival (PFS) was 2.8 months (95% CI, 1.5-4.1 months) and the median overall survival (OS) was 9.7 months (95% CI, 7.6-11.7 months). The most frequent adverse event was hand-foot syndrome (all-grade 26.6%; grade3 5%). The response of capecitabine, NLR, and PLR were observed as good prognostic markers of OS in univariate analysis (p<0.001, 0.004, and 0.002, respectively). The response of capecitabine and PLR were independent prognostic marker in multivariate analysis (Hazard ratio 2.757, 95% CI 1.357-5.599, p=0.005 and hazard ratio 2.091, 95% CI 1.231-3.552, p=0.006, respectively). Conclusions: The capecitabine monotherapy showed a moderate disease control and a tolerable toxicity profile as third line treatment for metastatic colorectal cancer. The response of capecitabine and PLR may be simple and useful prognostic index for metastatic colorectal cancer.

scholarly journals Combined fibrinogen concentration and neutrophil-lymphocyte ratio as a prognostic marker of gastric cancer

2015 ◽  
Vol 11 (2) ◽  
pp. 1537-1544 ◽  
Author(s):  
TAKAAKI ARIGAMI ◽  
YOSHIKAZU UENOSONO ◽  
DAISUKE MATSUSHITA ◽  
SHIGEHIRO YANAGITA ◽  
YASUTO UCHIKADO ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Prognostic Marker ◽  
Fibrinogen Concentration ◽  
Neutrophil Lymphocyte Ratio ◽  
Lymphocyte Ratio

scholarly journals FAN score comprising fibrosis-4 index, albumin–bilirubin score and neutrophil–lymphocyte ratio is a prognostic marker of urothelial carcinoma patients treated with pembrolizumab

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Atsunari Kawashima ◽  
Yoshiyuki Yamamoto ◽  
Mototaka Sato ◽  
Wataru Nakata ◽  
Yoichi Kakuta ◽  
...  
Keyword(s):  
Prognostic Factor ◽  
Urothelial Carcinoma ◽  
Prognostic Marker ◽  
Group Performance ◽  
Validation Cohort ◽  
Eastern Cooperative Oncology Group ◽  
Significant Prognostic Factor ◽  
Discovery Cohort ◽  
Neutrophil Lymphocyte Ratio ◽  
Lymphocyte Ratio

AbstractIt is important to identify prognostic and predictive markers of metastatic urothelial carcinoma (mUC) treated with immunocheckpoint inhibitors. We sought to establish a prognostic marker for patients with mUC treated with pembrolizumab based on only blood test results. We included 165 patients with mUC in the discovery cohort and 103 with mUC who were treated with pembrolizumab in the validation cohort. Multivariate and Cox regression analyses were used to analyse the data. In the discovery cohort, the fibrosis-4 index (hazard ratio [HR]: 2.13, 95% confidence interval [CI] 1.20–3.76, p = 0.010), albumin–bilirubin score (HR 1.91, 95% CI 1.27–2.88, p = 0.002), and neutrophil–lymphocyte ratio (HR: 1.84, 95% CI 1.22–2.79, p = 0.004) were independent significant prognostic factors. We established a ‘FAN score’ that included these three aforementioned items, which were assigned one point each. We divided patients into the 0–1 point (n = 116) and 2–3 points (n = 49) groups. The FAN score was a significant prognostic marker for cancer-specific survival (CSS) (HR 1.48, 95% CI 1.19–1.83, p < 0.001) along with the Eastern Cooperative Oncology Group Performance Status. The FAN score was also a prognostic factor of progression-free survival (PFS) (HR: 1.25, 95% CI 1.01–1.54, p = 0.036) along with the presence of liver metastasis. In the validation cohort, the FAN score was a significant prognostic factor for CSS (HR: 1.48, 95% CI 1.19–1.85, p = 0.001) and PFS (HR: 1.29, 95% CI 1.02–1.62, p = 0.034). We established the FAN score as a prognostic marker for patients with mUC treated with pembrolizumab.

Sign in / Sign up

Export Citation Format

Share Document